|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang Y, Li H, Hou S, Hu B, Liu J and Wang
J: The noncoding RNA expression profile and the effect of lncRNA
AK126698 on cisplatin resistance in non-small-cell lung cancer
cell. PLoS One. 8:e653092013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grutters JP, Kessels AG, Pijls-Johannesma
M, De Ruysscher D, Joore MA and Lambin P: Comparison of the
effectiveness of radiotherapy with photons, protons and carbon-ions
for non-small cell lung cancer: A meta-analysis. Radiother Oncol.
95:32–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vansteenkiste J, Crinò L, Dooms C,
Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P,
Veronesi G, et al: Role: Panel Members2nd ESMO Consensus Conference
on Lung Cancer: Early-stage non-small-cell lung cancer consensus on
diagnosis, treatment and follow-up. Ann Oncol. 25:1462–1474. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han SP, Tang YH and Smith R: Functional
diversity of the hnRNPs: Past, present and perspectives. Biochem J.
430:379–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Majumder M, Yaman I, Gaccioli F, Zeenko
VV, Wang C, Caprara MG, Venema RC, Komar AA, Snider MD and
Hatzoglou M: The hnRNA-binding proteins hnRNP L and PTB are
required for efficient translation of the Cat-1 arginine/lysine
transporter mRNA during amino acid starvation. Mol Cell Biol.
29:2899–2912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hutchison S, LeBel C, Blanchette M and
Chabot B: Distinct sets of adjacent heterogeneous nuclear
ribonucleoprotein (hnRNP) A1/A2 binding sites control 5′ splice
site selection in the hnRNP A1 mRNA precursor. J Biol Chem.
277:29745–29752. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han K, Yeo G, An P, Burge CB and Grabowski
PJ: A combinatorial code for splicing silencing: UAGG and GGGG
motifs. PLoS Biol. 3:e1582005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dreyfuss G, Kim VN and Kataoka N:
Messenger-RNA-binding proteins and the messages they carry. Nat Rev
Mol Cell Biol. 3:195–205. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chettouh H, Fartoux L, Aoudjehane L,
Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O,
Conti F, et al: Mitogenic insulin receptor-A is overexpressed in
human hepatocellular carcinoma due to EGFR-mediated dysregulation
of RNA splicing factors. Cancer Res. 73:3974–3986. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Z-Y, Cai L, Zhu J, Chen M, Chen J, Li
ZH, Liu XD, Wang SG, Bie P, Jiang P, et al: Fyn requires HnRNPA2B1
and Sam68 to synergistically regulate apoptosis in pancreatic
cancer. Carcinogenesis. 32:1419–1426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Golan-Gerstl R, Cohen M, Shilo A, Suh SS,
Bakàcs A, Coppola L and Karni R: Splicing factor hnRNP A2/B1
regulates tumor suppressor gene splicing and is an oncogenic driver
in glioblastoma. Cancer Res. 71:4464–4472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Santarosa M, Del Col L, Viel A, Bivi N,
D'Ambrosio C, Scaloni A, Tell G and Maestro R: BRCA1 modulates the
expression of hnRNPA2B1 and KHSRP. Cell Cycle. 9:4666–4673. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He Y, Brown MA, Rothnagel JA, Saunders NA
and Smith R: Roles of heterogeneous nuclear ribonucleoproteins A
and B in cell proliferation. J Cell Sci. 118:3173–3183. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tauler J, Zudaire E, Liu H, Shih J and
Mulshine JL: hnRNP A2/B1 modulates epithelial-mesenchymal
transition in lung cancer cell lines. Cancer Res. 70:7137–7147.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katsimpoula S, Patrinou-Georgoula M,
Makrilia N, Dimakou K, Guialis A, Orfanidou D and Syrigos KN:
Overexpression of hnRNPA2/B1 in bronchoscopic specimens: A
potential early detection marker in lung cancer. Anticancer Res.
29:1373–1382. 2009.PubMed/NCBI
|
|
17
|
Fielding P, Turnbull L, Prime W, Walshaw M
and Field JK: Heterogeneous nuclear ribonucleoprotein A2/B1
up-regulation in bronchial lavage specimens: A clinical marker of
early lung cancer detection. Clinical Cancer Res. 5:4048–4052.
1999.
|
|
18
|
Korshunov VA: Axl-dependent signalling: A
clinical update. Clin Sci (Lond). 122:361–368. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rothlin CV, Leighton JA and Ghosh S:
Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel
disease and colitis-associated cancer. Inflamm Bowel Dis.
20:1472–1480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu H, Tang H, Chen Y, Wang H and Han D:
High incidence of distal vaginal atresia in mice lacking Tyro3 RTK
subfamily. Molecular reproduction and development. 75:1775–1782.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang H, Chen SU, Chen Y, Wang H, Wu H,
Tang H, Xiong W, Ma J, Ge Y, Lu Q and Han D: The role of Tyro 3
subfamily receptors in the regulation of hemostasis and
megakaryocytopoiesis. Haematologica. 92:643–650. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mudduluru G, Ceppi P, Kumarswamy R,
Scagliotti GV, Papotti M and Allgayer H: Regulation of Axl receptor
tyrosine kinase expression by miR-34a and miR-199a/b in solid
cancer. Oncogene. 30:2888–2899. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He Y, Rothnagel JA, Epis MR, Leedman PJ
and Smith R: Downstream targets of heterogeneous nuclear
ribonucleoprotein A2 mediate cell proliferation. Mol Carcinog.
48:167–179. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Man YG, Martinez A, Avis IM, Hong SH,
Cuttitta F, Venzon DJ and Mulshine JL: Phenotypically different
cells with heterogeneous nuclear ribonucleoprotein A2/B1
overexpression show similar genetic alterations. Am J Respir Cell
Mol Biol. 23:636–645. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Linger RM, Cohen RA, Cummings CT, Sather
S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA,
Merrick DT, et al: Mer or Axl receptor tyrosine kinase inhibition
promotes apoptosis, blocks growth and enhances chemosensitivity of
human non-small cell lung cancer. Oncogene. 32:3420–3431. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
